Cellectar Biosciences, Inc. — Director's Dealing 2022

Jan 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2022-01-25

Reporting Person: Longcor Jarrod (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-25	Stock option (right to buy)	$0.55	A	475000	Acquired	2032-01-25	Common Stock (475000)	Direct

Footnotes

F1: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.